HDAC2 and triple-negative breast carcinoma: Functional studies revealed that the binding of the YY1/p300/histone deacetylase 2 (HDAC2) complex to the GUSBP11 promoter is responsible for its reduced expression in triple-negative breast cancer cell lines.